Professor Per Morten Sandset is Vice-Rector of the University of Oslo for the period 2017-2025.
See also the following URL: http://ous-research.no/riim/
I'm blogging with the rest of the team at Rector's blog.
Publications
-
-
Shapiro, Amy D.; Nakar, Charles; Parker, Joseph M.; Thibaudeau, Karen; Crea, Roberto & Sandset, Per Morten
(2023).
Plasminogen, human-tvmh for the treatment of children and adults with plasminogen deficiency type 1.
Haemophilia.
ISSN 1351-8216.
doi:
10.1111/hae.14849.
Full text in Research Archive
-
-
-
Pradier, Michelle; Rodger, Marc A.; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep & Kahn, Susan R.
[Show all 10 contributors for this article]
(2023).
Performance and Head-to-Head Comparison of Three Clinical Models to Predict Occurrence of Postthrombotic Syndrome: A Validation Study.
Thrombosis and Haemostasis.
ISSN 0340-6245.
123(7),
p. 692–699.
doi:
10.1055/a-2039-3388.
-
-
-
-
-
Ng, Sara; Rodger, Marc A.; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep & Kahn, Susan R.
[Show all 10 contributors for this article]
(2022).
External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome.
Thrombosis and Haemostasis.
ISSN 0340-6245.
122(8),
p. 1379–1383.
doi:
10.1055/a-1738-1313.
-
de la Morena-Barrio, Maria Eugenia; Suchon, Pierre; Jacobsen, Eva-Marie; Iversen, Nina; Miñano, Antonia & de la Morena-Barrio, Belén
[Show all 17 contributors for this article]
(2022).
Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays.
Blood.
ISSN 0006-4971.
140(2),
p. 140–151.
doi:
10.1182/blood.2021014708.
Show summary
Antithrombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogenic variants are not detected by routine functional
methods. We have identified 2 new SERPINC1 variants, p.Glu227Lys and p.Asn224His, in 4 unrelated thrombophilic patients with early and recurrent thrombosis that had normal
antithrombin activity. In one case, the mutation was identified by whole genome sequencing,
while in the 3 remaining cases, the mutation was identified by sequencing SERPINC1
based on a single functional positive finding supporting deficiency. The 2 variants shared a
common functional defect, an impaired or null N-glycosylation of Asn224 according to a
eukaryotic expression model. Carriers had normal anti-FXa or anti-FIIa activities but
impaired anti-FVIIa activity and a detectable loss of inhibitory function when incubating the
plasma for 1 hour at 41°C. Moreover, the b glycoform of the variants, lacking 2 N-glycans,
had reduced secretion, increased heparin affinity, no inhibitory activity, and a potential
dominant–negative effect. These results explain the increased thrombin generation
observed in carriers. Mutation experiments reflected the role that Lysine residues close to the N-glycosylation sequon
have in impairing the efficacy of N-glycosylation. Our study shows new elements involved in the regulation of
N-glycosylation, a key posttranslational modification that, according to our results, affects folding, secretion, and
function, providing new evidence of the pathogenic consequence of an incorrect N-glycosylation of antithrombin. This study supports that antithrombin deficiency is underestimated and encourages the development of new functional and
genetic tests to diagnose this severe thrombophilia.
-
Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie
[Show all 15 contributors for this article]
(2022).
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up.
Journal of Thrombosis and Haemostasis.
ISSN 1538-7933.
20(5),
p. 1166–1181.
doi:
10.1111/jth.15666.
Full text in Research Archive
Show summary
Background
There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban for 30 months, after initial 6 months of full-dose treatment.
Methods
We included 298 patients with cancer and any type of VTE in a single arm interventional clinical trial. All patients were treated with full-dose apixaban (5 mg twice daily) for 6 months. Total 196 patients with active cancer after 6 months treatment continued with apixaban 2.5 mg twice daily for another 30 months. The main endpoints were recurrent VTE, major bleeding and clinically relevant non-major bleeding.
Results
During the 30 months of treatment with low-dose apixaban 14 (7.6%; 95% confidence interval (CI) 4.0%–11.7%) patients experienced recurrent VTE, six (3.1%; 95% CI 1.1%–6.5%) experienced major bleeding and 16 (8.1%, 95% CI: 4.7%–12.8%) experienced clinically relevant non-major bleeding. The incidence rate per person month of recurrent VTE was 0.8% (95% CI 0.41–1.6) at 2–6 months with full-dose apixaban, and 1.0% (95% CI 0.5–1.9) at 7–12 months with low-dose apixaban. The incidence rate of major bleeding was 1.1% (95% CI 0.6–2.0) at 2–6 months, and 0.3% (95% CI 0.1–1.0) at 7–12 months. Between 12 and 36 months the incidence rate of recurrent VTE and major bleedings remained low.
Conclusion
Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.
-
-
-
Skaga, Nils Oddvar; Holtan, Anders; Haug, Inger & Sandset, Per Morten
(2022).
MEDIKAMENTBRUK VED KRITISK BLØDNING OG REVERSERING AV ANTITROMBOTISKE LEGEMIDLER – PROTOKOLL I TRAUMEMOTTAKET VED OUS ULLEVÅL.
Kirurgen.
ISSN 1504-8888.
p. 20–21.
-
Martin, Karlyn A.; Beyer-Westendorf, Jan; Davidson, Bruce L.; Huisman, Menno V.; Sandset, Per Morten & Moll, S.
(2021).
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
Journal of Thrombosis and Haemostasis.
ISSN 1538-7933.
19(8),
p. 1874–1882.
doi:
10.1111/jth.15358.
-
-
Andresen, Marianne Seierstad; Sletten, Marit; Sandset, Per Morten; Iversen, Nina; Stavik, Benedicte & Tinholt, Mari
(2021).
Coagulation Factor v (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells.
Thrombosis and Haemostasis.
ISSN 0340-6245.
122(8),
p. 1288–1295.
doi:
10.1055/a-1707-2130.
-
-
-
-
-
-
-
-
Bøhn, Siv Kjølsrud; Thune, Inger; Flote, Vidar Gordon; Frydenberg, Hanne; Bertheussen, Gro Falkener & Husøy, Anders
[Show all 12 contributors for this article]
(2021).
Effects of a One-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors - A Randomized Controlled Trial.
TH Open.
ISSN 2512-9465.
5(1),
p. e14–e23.
doi:
10.1055/s-0040-1721782.
Full text in Research Archive
Show summary
Introduction Physical activity may reduce the development of breast cancer. Whereas hypercoagulability has been linked to adverse outcomes in breast cancer patients, the effects of physical activity on their hemostatic factors are unknown. The study aimed to assess whether long-term (1 year) physical activity can affect hemostatic factors in breast cancer patients.
Methods Fifty-five women (35–75 years) with invasive breast cancer stage I/II were randomized to a physical activity intervention (n = 29) lasting 1 year or to a control group (n = 26), and analyzed as intention to treat. Fibrinogen, factor VII antigen, tissue factor pathway inhibitor, and von Willebrand factor (VWF) antigen as well as prothrombin fragment 1 + 2, the endogenous thrombin potential and D-dimer, were measured in plasma before intervention (baseline), and then after 6 and 12 months.
Results Maximal oxygen uptake (measure of cardiorespiratory fitness) decreased the first 6 months among the controls, but remained stable in the intervention group. We found no significant differences between the two study groups regarding any of the hemostatic factors, except a significantly higher increase in factor VII antigen in the intervention group. The effect of the intervention on VWF was, however, significantly affected by menopausal stage, and a significant effect of the intervention was found on VWF among postmenopausal women, even after adjustment for dietary intake.
Conclusion Long-term physical activity had no effect on the majority of the hemostatic factors measured, but led to increased plasma concentrations of factor VII antigen and prevented an increase in VWF concentration after breast cancer treatment in postmenopausal women. The clinical impact of these findings for risk of vascular thrombosis warrants further studies.
-
-
-
-
-
-
-
Thorsen, Lene; Haugnes, Hege Sagstuen; Fosså, Sophie Dorothea; Brydøy, Marianne; Tandstad, Torgrim & Wisløff, Torbjørn
[Show all 13 contributors for this article]
(2020).
Thromboembolic events after high-intensity training duringcisplatin-based chemotherapy for testicular cancer: Casereports and review of the literature.
International Journal of Cancer.
ISSN 0020-7136.
147(11),
p. 3189–3198.
doi:
10.1002/ijc.33151.
Full text in Research Archive
Show summary
The randomized “Testicular cancer and Aerobic and Strength Training trial” (TAST‐trial) aimed to evaluate the effect of high‐intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin‐based chemotherapy (CBCT) for testicular cancer (TC). Here, we report on an unexpected high number of thromboembolic (TE) events among patients randomized to the intervention arm, and on a review of the literature on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were randomized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling session. The exercise intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was prematurely discontinued after inclusion of 19 of the planned 94 patients, with nine patients randomized to the intervention arm and 10 to the control arm. Three patients in the intervention arm developed TE complications; two with pulmonary embolism and one with myocardial infarction. All three patients had clinical stage IIA TC. No TE complications were observed among patients in the control arm. Our observations indicate that high‐intensity aerobic training during CBCT might increase the risk of TE events in TC patients, leading to premature closure of the TAST‐trial.
-
-
-
-
-
-
-
-
Garabet, Lamya Samir Noori; Ghanima, Waleed Khalid; Hellum, Marit Synnøve; Sandset, Per Morten; Bussel, James B. & Tran, Hoa Thi Tuyet
[Show all 7 contributors for this article]
(2019).
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Platelets.
ISSN 0953-7104.
doi:
10.1080/09537104.2019.1639655.
-
-
Godolphin, Peter J.; Bath, Philip M.; Algra, Ale; Berge, Eivind; Brown, Christopher Martin & Chalmers, John
[Show all 19 contributors for this article]
(2019).
Outcome assessment by central adjudicators versus site investigators in stroke trials: A systematic review and meta-analysis.
Stroke.
ISSN 0039-2499.
50(8),
p. 2187–2196.
doi:
10.1161/STROKEAHA.119.025019.
Full text in Research Archive
Show summary
Background and Purpose—
In randomized stroke trials, central adjudication of a trial’s primary outcome is regularly implemented. However, recent evidence questions the importance of central adjudication in randomized trials. The aim of this review was to compare outcomes assessed by central adjudicators with outcomes assessed by site investigators.
Methods—
We included randomized stroke trials where the primary outcome had undergone an assessment by site investigators and central adjudicators. We searched MEDLINE, EMBASE, CENTRAL (Cochrane Central Register of Controlled Trials), Web of Science, PsycINFO, and Google Scholar for eligible studies. We extracted information about the adjudication process as well as the treatment effect for the primary outcome, assessed both by central adjudicators and by site investigators. We calculated the ratio of these treatment effects so that a ratio of these treatment effects >1 indicated that central adjudication resulted in a more beneficial treatment effect than assessment by the site investigator. A random-effects meta-analysis model was fitted to estimate a pooled effect.
Results—
Fifteen trials, comprising 69 560 participants, were included. The primary outcomes included were stroke (8/15, 53%), a composite event including stroke (6/15, 40%) and functional outcome after stroke measured on the modified Rankin Scale (1/15, 7%). The majority of site investigators were blind to treatment allocation (9/15, 60%). On average, there was no difference in treatment effect estimates based on data from central adjudicators and site investigators (pooled ratio of these treatment effects=1.02; 95% CI, [0.95–1.09]).
Conclusions—
We found no evidence that central adjudication of the primary outcome in stroke trials had any impact on trial conclusions. This suggests that potential advantages of central adjudication may not outweigh cost and time disadvantages in stroke studies if the primary purpose of adjudication is to ensure validity of trial findings.
-
-
Eilertsen, Anette Løken; Dahm, Anders Erik A; Høibraaten, Else; Lofthus, Cathrine Marie; Mowinckel, Marie-Christine & Sandset, Per Morten
(2019).
Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment.
Blood Coagulation and Fibrinolysis.
ISSN 0957-5235.
30(1),
p. 17–23.
doi:
10.1097/MBC.0000000000000784.
-
-
Garabet, Lamya Samir Noori; Ghanima, Waleed Khalid; Jonassen, Christine Monceyron; Skov, Vibe; Holst, René & Mowinckel, Marie-Christine
[Show all 12 contributors for this article]
(2019).
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.
Platelets.
ISSN 0953-7104.
30(2),
p. 206–212.
doi:
10.1080/09537104.2017.1394451.
-
Schultz, Nina Haagenrud; Holme, Pål Andre; Bjørnsen, Stine; Henriksson, Carola; Sandset, Per Morten & Jacobsen, Eva-Marie
(2018).
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.
Platelets.
ISSN 0953-7104.
doi:
10.1080/09537104.2018.1557618.
-
-
-
-
-
Andersen, Elisabeth; Dugarte, Maria Eugenia Chollet; Myklebust, Christiane Filion; Pinotti, Mirko; Bernardi, Francesco & Chuansumrit, Ampaiwan
[Show all 9 contributors for this article]
(2018).
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency.
Thrombosis and Haemostasis.
ISSN 0340-6245.
118(4),
p. 664–675.
doi:
10.1055/s-0038-1637690.
-
-
Wik, Hilde Skuterud; Enden, Tone Rønnaug; Ghanima, Waleed Khalid; Engeseth, Marit; Kahn, Susan R. & Sandset, Per Morten
(2018).
Diagnostic scales for the post-thrombotic syndrome.
Thrombosis Research.
ISSN 0049-3848.
164,
p. 110–115.
doi:
10.1016/j.thromres.2017.10.022.
-
-
-
-
Utne, Kristin Kornelia; Dahm, Anders Erik A; Wik, Hilde Skuterud; Jelsness-Jørgensen, Lars-Petter; Sandset, Per Morten & Ghanima, Waleed Khalid
(2018).
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.
Thrombosis Research.
ISSN 0049-3848.
163,
p. 6–11.
doi:
10.1016/j.thromres.2018.01.013.
-
-
Amundsen, Erik Koldberg; Skadberg, Øyvind; Ghanima, Waleed Khalid; Frønæs, Synne Grønvold; Dahm, Anders Erik A & Tøsdal, Margunn Bye
[Show all 9 contributors for this article]
(2018).
D-Dimer: Aldersjusterte beslutningsgrenser ved diagnostikk av venøs tromboembolisme?
Klinisk Biokemi i Norden.
ISSN 1101-2013.
30(1),
p. 26–36.
-
-
Schultz, Nina Haagenrud; Tran, Hoa Thi Tuyet; Bjørnsen, Stine; Henriksson, Carola Elisabeth; Sandset, Per Morten & Holme, Pål Andre
(2017).
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Research and Practice in Thrombosis and Haemostasis (RPTH).
ISSN 2475-0379.
1(1),
p. 49–56.
doi:
10.1002/rth2.12015.
-
Tikkinen, Kari A. O.; Craigie, Samantha; Agarwal, Arnav; Siemieniuk, Reed A.C.; Cartwright, Rufus & Violette, Philippe D.
[Show all 16 contributors for this article]
(2017).
Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis.
European Urology.
ISSN 0302-2838.
73(2),
p. 236–241.
doi:
10.1016/j.eururo.2017.02.025.
-
Sagedal, Solbjørg; Sandvik, Leiv; Klingenberg, Olav & Sandset, Per Morten
(2017).
β-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane.
Scandinavian Journal of Clinical and Laboratory Investigation.
ISSN 0036-5513.
77(8),
p. 679–684.
doi:
10.1080/00365513.2017.1397288.
-
-
View all works in Cristin
-
-
-
-
-
-
-
Cui, Xueyan; Myklebust, June Helen; Munthe, Ludvig A; Schjesvold, Fredrik Hellem; Tjønnfjord, Geir Erland & Stavik, Benedicte
[Show all 7 contributors for this article]
(2022).
Single-cell sequencing reveals procoagulant microenvironment in precursor stages of multiple myeloma .
-
-
-
-
Andresen, Marianne Seierstad; Mowinckel, Marie-Christine; Stavik, Benedicte; Sandset, Per Morten & Dugarte, Maria Eugenia Chollet
(2022).
Evaluation of Pharmacological Enhancers of Mutated Factor VII Activity ex vivo.
Research and Practice in Thrombosis and Haemostasis (RPTH).
ISSN 2475-0379.
-
-
-
-
andersen, elisabeth; Mowinckel, Marie-Christine; Stavik, Benedicte; Sandset, Per Morten & Dugarte, Maria Eugenia Chollet
(2021).
High-throughput Screening for Pharmacological Enhancers of Mutated Factor VII Activity.
Research and Practice in Thrombosis and Haemostasis (RPTH).
ISSN 2475-0379.
5.
-
-
-
andersen, elisabeth; Dugarte, Maria Eugenia Chollet; Sletten, Marit; Stavik, Benedicte; Myklebust, Christiane Fillion & Skarpen, Ellen
[Show all 11 contributors for this article]
(2020).
Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding.
Blood.
ISSN 0006-4971.
136.
doi:
10.1182/blood-2020-139219.
-
Stavik, Benedicte; Sagen, Ellen Lund; Cui, Xueyan; Holm, Sverre; Dahl, Tuva Børresdatter & Iversen, Nina
[Show all 8 contributors for this article]
(2020).
Tissue Factor Pathway Inhibitor induces secretion of pro-inflammatory cytokines in monocyte-derived macrophages.
Arteriosclerosis, Thrombosis and Vascular Biology.
ISSN 1079-5642.
40.
-
Dugarte, Maria Eugenia Chollet; andersen, elisabeth; de la Morena-Barrio, Maria Eugenia; Bravo-Perez, Carlos; Mowinckel, Marie-Christine & Myklebust, Christiane Fillion
[Show all 12 contributors for this article]
(2020).
Characterizing Coagulation FVII from iPSC-Hepatocytes-like Cells: Setting the Basis for Cell Therapy Development.
Blood.
ISSN 0006-4971.
136.
doi:
10.1182/blood-2020-139211.
-
Kakkos, Stavros K.; Gohel, Manjit; Baekgaard, Niels; Bauersachs, Rupert; Bellmunt-Montoya, Sergi & Black, Stephen A
[Show all 16 contributors for this article]
(2020).
Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis.
European Journal of Vascular and Endovascular Surgery.
ISSN 1078-5884.
61(1),
p. 9–82.
doi:
10.1016/j.ejvs.2020.09.023.
-
-
Tinholt, Mari; Stavik, Benedicte; Sletten, Marit; Garred, Øystein; Tekpli, Xavier & Kristensen, Vessela N.
[Show all 9 contributors for this article]
(2019).
Coagulation factor V is associated with immune response and tumor lymphocyte recruitment in breast cancer.
-
-
Andresen, Marianne Seierstad; Stavik, Benedicte; Sletten, Marit; Tinholt, Mari; Sandset, Per Morten & Iversen, Nina
[Show all 7 contributors for this article]
(2019).
MicroRNA-494 upregulates TFPI-2 expression in MCF-7 breast cancer cells.
-
Sandset, Per Morten & Dahm, Anders Erik Astrup
(2019).
Is venous thromboembolism a problem in patients with cancer in palliative care?
The Lancet Haematology.
ISSN 2352-3026.
doi:
10.1016/S2352-3026(18)30218-7.
-
-
Sacco, Simona; Merki-Feld, Gabriele S.; Ægidius, Karen Lehrmann; Bitzer, Johannes; Canonico, Marianne & Kurth, Tobias
[Show all 15 contributors for this article]
(2018).
Correction to: Hormonal contraceptives and risk of ischemic stroke in women with migraine: A consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC) (Journal of Headache and Pain (2018) 18 (108) DOI: 10.1186/s10194-017-0815-1).
The Journal of Headache and Pain.
ISSN 1129-2369.
19(1).
doi:
10.1186/s10194-018-0912-9.
-
Stavik, Benedicte; Tinholt, Mari; Skjelland, Mona; Espevik, Terje; Sandset, Per Morten & Halvorsen, Bente
[Show all 7 contributors for this article]
(2018).
Coagulation factors in human atherosclerotic plaques – a potential link to inflammation?
-
-
-
-
Dahm, Anders Erik A; Jacobsen, Eva-Marie; Jacobsen, Anne Flem; Skuterud Wik, Hilde & Sandset, Per Morten
(2017).
High complement C3 increases the risk for postnatal venous thrombosis.
View all works in Cristin
Published
July 31, 2017 5:35 PM
- Last modified
Oct. 12, 2021 10:23 AM